Name - Ibere Pharmaceuticals
Current / Former Name: Ibere Pharmaceuticals (Current)
Address: 340 Madison Avenue, 19th Floor, New York, NY 10173
Phone Number: (212) 651-0300
Investor Relations Contact: N/A
Website - N/A
Warrant Details
Warrant Symbol: IBER.WS
Warrants Listed: 4,600,000
Ratio: 1-for-1
Cusip Number: 451103 11 4
ISIN Number: US4511031143
Parent Stock Symbol: IBER
Underlying Stock CUSIP: 451103 10 6
Expiry Date - March 2, 2023 (Liquidated)
Exercise Price: $11.50 USD
Synopsis & Listing Information
Ibere Pharmaceuticals was a blank-check company formed to target patient-centric assets in the pharmaceutical and life sciences sectors, with an operational emphasis on therapeutic applications across North America.
Listing History: The company completed its IPO on March 2, 2021. The public warrants separated and traded independently on the New York Stock Exchange under the ticker symbol IBER.WS.
Business Combination: The company failed to execute a definitive business combination within its allowed contractual timeline due to valuation shifts across small-cap biotechnology assets.
Ticker Change: The symbol remained IBER.WS until the corporate structure dissolved.
Reverse Split Adjustment: No adjustments occurred because a business combination was not finalized.
Current Status: Defunct. Ibere Pharmaceuticals officially dissolved and liquidated its trust account on March 2, 2023. The public warrants expired completely worthless.
Current / Former Name: Ibere Pharmaceuticals (Current)
Address: 340 Madison Avenue, 19th Floor, New York, NY 10173
Phone Number: (212) 651-0300
Investor Relations Contact: N/A
Website - N/A
Warrant Details
Warrant Symbol: IBER.WS
Warrants Listed: 4,600,000
Ratio: 1-for-1
Cusip Number: 451103 11 4
ISIN Number: US4511031143
Parent Stock Symbol: IBER
Underlying Stock CUSIP: 451103 10 6
Expiry Date - March 2, 2023 (Liquidated)
Exercise Price: $11.50 USD
Synopsis & Listing Information
Ibere Pharmaceuticals was a blank-check company formed to target patient-centric assets in the pharmaceutical and life sciences sectors, with an operational emphasis on therapeutic applications across North America.
Listing History: The company completed its IPO on March 2, 2021. The public warrants separated and traded independently on the New York Stock Exchange under the ticker symbol IBER.WS.
Business Combination: The company failed to execute a definitive business combination within its allowed contractual timeline due to valuation shifts across small-cap biotechnology assets.
Ticker Change: The symbol remained IBER.WS until the corporate structure dissolved.
Reverse Split Adjustment: No adjustments occurred because a business combination was not finalized.
Current Status: Defunct. Ibere Pharmaceuticals officially dissolved and liquidated its trust account on March 2, 2023. The public warrants expired completely worthless.
American Financial News
Loading the latest American market news...
American Financial News
Loading the latest American market news...